Posted by Michael Wonder on 11 Mar 2022
Allogene Therapeutics receives FDA fast track designation for its first solid tumour candidate, ALLO-316 in the treatment of renal cell carcinoma
10 March 2022 - ALLO-316 is an allogeneic CAR T therapy candidate targeting CD70, which has broad potential application across a variety of solid tumours and haematologic malignancies.
Allogene Therapeutics today announced that the U.S. FDA has granted fast track designation to ALLO-316, the Company’s first AlloCAR T solid tumour clinical candidate for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma.
